Search Results
Oct 29, 2025, 08:48 ET Akston Pioneers a New Generation of Cancer Therapy for Dogs in Clinical Trial Launch
clinical study to evaluate a first–in–class Ambifect® immuno-enhancing therapy targeting PD-L1 in dogs with solid tumors. Built on Akston's proprietary Fc–fusion protein platform, it is designed as an intramuscular injection that aims to transform access to advanced cancer care by reducing treatment
More news about: Akston
Oct 29, 2025, 07:00 ET UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
solution for injection is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing
More news about: UCB
Oct 29, 2025, 04:00 ET BC.GAME CIS Appoints KRASAVA as Brand Ambassador
Russian-speaking world, transforming match moments and player journeys into stories that travel far beyond any single league. As the founder of KRASAVA FC and a champion of youth development through academy projects, he uses football as both a language and a bridge—connecting players, fans, and communities.
More news about: BC.GAME
Oct 28, 2025, 10:04 ET WeatherPromise and HomeToGo Expand Partnership to France and the Netherlands
segment, HomeToGo_PRO, with its AI-powered B2C marketplace. HomeToGo is the official travel partner and top sponsor of German Bundesliga football club 1. FC Union Berlin. HomeToGo_PRO offers innovative software & tech-enabled service solutions for everyone who wants to be successful
More news about: WeatherPromise
Oct 28, 2025, 09:00 ET Clarifai and Vultr Showcase Record-Breaking AI Inference Performance on GPUs at NVIDIA GTC AI Conference
https://mma.prnewswire.com/media/837665/Clarifai_Logo_FC_Logo.jpg
More news about: Clarifai
Oct 28, 2025, 06:30 ET NEW ERA ANNOUNCES FC BARCELONA AS OFFICIAL HEADWEAR LICENSEE
brand New Era officially partners with FC Barcelona to launch an exclusive headwear collection, marking its appointment as the club's official headwear licensee. Rooted in the vibrant spirit of the city, New Era blends its design expertise with the cultural legacy of FC Barcelona, bringing together the club's
More news about: New Era Cap Company Limited
Oct 28, 2025, 06:30 ET NEW ERA ANUNCIA SU ACUERDO CON EL FC BARCELONA COMO LICENSEE OFICIAL DE GORRAS
colaboración oficial con el FC Barcelona para el lanzamiento de una colección exclusiva de gorras, marcando así su nombramiento como licenciatario oficial de gorras del club. Inspirada en el espíritu vibrante de la ciudad, New Era combina su experiencia en diseño con el legado cultural del FC Barcelona, uniendo
More news about: New Era Cap Company Limited
Oct 24, 2025, 17:25 ET Sports Performance Hub announces landmark agreement with the City of Homestead: a $280 million private investment set to redefine sports, education and community in South Florida
tennis and football, a boarding school, residences, a 100-room hotel, a medical and mental health center, and a 10,000-seat stadium that will host Miami FC, which will train and play its home matches in the complex. "Homestead represents the spirit of resilience that defines both sport
More news about: Sports Performance Hub
Oct 24, 2025, 11:27 ET BingX расширяет предложения в сфере RWA, предоставляя трейдерам больше гибкости
помогают пользователям повышать эффективность и уверенность в торговле. В 2024 году BingX стала официальным криптопартнёром футбольного клуба Chelsea FC, отметив важный шаг в развитии спортивного спонсорства. Подробнее: https://bingx.com
More news about: BingX
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
of Response to the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 1-Year ICONIC-TOTAL Findings. Oral presentation (Presentation FC01.1G) at the 2025 Fall Clinical Dermatology Conference. October 2025.
More news about: Johnson & Johnson
Oct 24, 2025, 05:01 ET BingX укрепляет лидерство в сфере Web3 и искусственного интеллекта, достигнув 3 миллионов ранних пользователей и объёма копитрейдинга в $80 миллиардов за третий квартал
инновационные инструменты для повышения эффективности и уверенности пользователей. В 2024 году BingX стала официальным криптопартнером футбольного клуба Chelsea FC, что ознаменовало дебют компании в мире спортивного спонсорства. Подробнее на сайте:
More news about: BingX
Oct 24, 2025, 04:37 ET BingX lanza la tarifa cero para el trading de BTC, ETH y BNB con recompensas diarias
innovadoras diseñadas para mejorar el rendimiento y la confianza. En 2024, BingX se convirtió en orgulloso partner como exchange cripto oficial del Chelsea FC, marcando su debut en el mundo de los deportes. Para más información, por favor visita
More news about: BingX
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
About HCB101: A Differentiated CD47-SIRPα BlockadeHCB101 is a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio's proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood
More news about: HanchorBio Inc.
Oct 23, 2025, 08:31 ET BingX, líder en IA Web3 con 3 millones de usuarios y USD 80 mil millones en volumen de copy trading en el último trimestre
innovadoras diseñadas para mejorar el rendimiento y la confianza. En 2024, BingX se convirtió en orgulloso partner como exchange cripto oficial del Chelsea FC, marcando su debut en el mundo de los deportes. Para más información, por favor
More news about: BingX
Oct 23, 2025, 08:25 ET BingX, líder em IA Web3 com 3 milhões de usuários e US$ 80 bilhões em volume de copy trading no último trimestre
ferramentas inovadoras projetadas para aumentar o desempenho e a confiança. Em 2024, a BingX tornou-se a parceira principal do Chelsea FC, marcando sua estreia no mundo dos esportes. Para mais informações, visite
More news about: BingX
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology (SCI Impact Factor 40.4; for reference, leading journals in the
More news about: HanchorBio Inc.
Oct 22, 2025, 19:00 ET 스카치 브랜드, 접착 솔루션 및 산업 혁신 100주년 기념
multimedia:https://www.prnewswire.com/kr/news-releases/uC2A4uCE74uCE58u002DuBE0CuB79CuB4DCu002Cu002DuC811uCC29u002DuC194uB8E8uC158u002DuBC0Fu002DuC0B0uC5C5u002DuD601uC2E0u002Du0031u0030u0030uC8FC-302589795.html
More news about: 3M Company
Oct 22, 2025, 05:09 ET Drug Prevents Congenital Heart Block Recurrence in a High-Risk Pregnancy
newborn. The researchers who treated the pregnant mother say this is the first case of using the drug, rozanolixizumab, a neonatal Fc receptor (FcRn) inhibitor, to prevent congenital heart block. Publishing in the journal Annals of the Rheumatic Diseases online
More news about: NYU Langone Health System
Oct 21, 2025, 11:50 ET Pioneering Physician-Scientist Dr. Francis S. Collins Joins ImmunoBrain Board of Directors
immune function plays a key role in brain aging and neurodegenerative diseases. These discoveries led to the development of IBC-Ab002, a proprietary Fc-modified anti-PD-L1 antibody, designed and optimized by ImmunoBrain for the treatment of neurological diseases, based on the understanding of its mechanism
More news about: ImmunoBrain Checkpoint Inc.
Oct 21, 2025, 07:30 ET Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting
https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.7 Mueller J.K., et al. Persona OsseoTi Keel Tibia Provides Stable
More news about: Zimmer Biomet Holdings, Inc.
Oct 21, 2025, 07:00 ET HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
Novelty of HCB101: An Innovative Fusion Protein Design Developed using HanchorBio's proprietary FBDB™ (Fc-Based Designed Biologics) platform, HCB101 is an engineered SIRPα/CD47 fusion protein designed to precisely modulate the immune system's recognition
More news about: HanchorBio Inc.
Oct 20, 2025, 09:22 ET BingX Academy 2.0 lançada para elevar o aprendizado sobre Web3 e criptomoedas
ferramentas inovadoras projetadas para aumentar o desempenho e a confiança. Em 2024, a BingX tornou-se a parceira principal do Chelsea FC, marcando sua estreia no mundo dos esportes. Para mais informações, visite www.bingx.com
More news about: BingX
Oct 20, 2025, 09:19 ET BingX lanza su Academia 2.0 para mejorar el aprendizaje de Web3 y criptomonedas
innovadoras diseñadas para mejorar el rendimiento y la confianza. En 2024, BingX se convirtió en orgulloso partner como exchange cripto oficial del Chelsea FC, marcando su debut en el mundo de los deportes. Para más información, por favor visita
More news about: BingX
Oct 20, 2025, 09:05 ET At eMazzanti ASPIRE 2025, More Than 200 Attendees Learned How to Turn Technology into Competitive Advantage
Keynote speaker Olympic Silver Medalist Jack Alexy kicked off ASPIRE 2025, addressing the need for persistence and resiliency in the face of setbacks, and FC Motown Co-Founder and CFO Dan Karosen shared how bold leadership, vision, decisions, culture, and strategies drove the rise of a semi-professional club
More news about: eMazzanti Technologies
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
About HCB101: A Differentiated CD47-SIRPα BlockadeHCB101 is a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio's proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood
More news about: HanchorBio Inc.